Suven, US Firm to Develop Cardiovascular Drugs (India)
This article was originally published in PharmAsia News
India's Suven Life Sciences has announced that it plans to sign a formal drug-development deal with a yet-to-be-named major, U.S.-based pharmaceutical company. As part of the alliance, both companies will take new cardiovascular drugs from drug discovery through the preclinical stage of testing. In preparation for the agreement, Suven will increase the size of its drug development center by about 500 researchers. Suven has also announced it will be expanding its research and development deal with Eli Lilly. Currently, the two companies work together on several potential drugs for central nervous system disorders such as Alzheimer's, schizophrenia, and depression. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.